Month: September 2026

FORT WORTH, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) — CorVel Corporation (NASDAQ: CRVL), a national provider of risk management and healthcare solutions, today announced the availability of its Care^MC Accelerator for Guidewire ClaimCenter, enabling Managed Care services to be initiated and managed directly within the claims workflow.

Designed for Guidewire Cloud and aligned with Guidewire standards, the Care^MC Accelerator connects claims activity with Managed Care operations through secure Single Sign‑On (SSO) and structured data exchange. This integration delivers a streamlined experience where key actions and information are available at the point of decision, reducing friction and improving workflow efficiency.

Streamlined Access and Data Exchange

The Care^MC Accelerator, now available on Guidewire Marketplace, enables carriers to connect claims and Managed Care processes through:

• Direct access to CorVel Managed Care services from within ClaimCenter
• Secure SSO to support streamlined navigation across systems
• Automated transfer of claim and injury data to initiate services
• Real‑time return of Managed Care status updates, recommendations, and outcomes

By coordinating how information moves across systems, teams gain clearer insight into case activity and can take action without unnecessary disruption.

Practical Benefits for Claims and Managed Care Teams

With this integration, users can:

• Initiate and coordinate care services within their existing claims environment
• Eliminate duplicate data entry and reduce administrative steps
• Track Managed Care activity in real time
• Make faster, more informed decisions with guided visibility into care activity

Scalable Integration Built for Adoption

CorVel’s Accelerator supports flexible implementation and long‑term scalability. By leveraging Guidewire integration standards, the Care^MC Accelerator reduces technical complexity while allowing carriers to configure workflows that align with their operating models.

Key advantages include:

• Faster and more predictable implementation timelines
• Reduced demand on IT resources
• Configurable workflows and business rules
• Simplified evaluation and deployment through the Guidewire Marketplace

Supporting Modern Claims Operations

This integration enables managed care to function as a coordinated part of the claims process rather than a separate downstream activity. Teams benefit from improved continuity and greater confidence that medical aspects of a claim are being addressed alongside claims handling.

“Moving to CorVel has never been easier, not because claims environments are simple, but because our integrations are designed to align with how carriers operate,” said Ron Wojciechowski, Senior Vice President of Payer Technical Solutions at CorVel. “Our Care^MC Accelerator supports efficient adoption while helping teams stay focused on outcomes.”

Additional details are available through Guidewire Marketplace.

About CorVel
CorVel Corp. applies technology, including artificial intelligence, machine learning, and natural language processing, to enhance the management of episodes of care and related health care costs. We partner with employers, third-party administrators, insurance companies, and government agencies in managing workers’ compensation and health, auto, and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support our partners and their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change. Such forward-looking statements include, but are not limited to, improved productivity resulting from automation and augmentation across enterprise business systems. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June 30, 2025, September 30, 2025, and December 31, 2025. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com

Award Strengthens Regional Supply Chain and Advances Edible Garden’s Zero-Waste Inspired® Mission and Farm-to-Formula® Platform

BELVIDERE, NJ, Sept. 22, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded fresh-cut herb business through an additional Walmart distribution center serving the Upper Midwest. The award builds upon the Company’s recently announced expansion with Walmart in the Mid-Atlantic region and extends Edible Garden’s growing retail presence into the Upper Midwest.

The additional distribution center will be serviced by Edible Garden Heartland in Grand Rapids, Michigan, further diversifying the facility’s customer base while supporting the Company’s strategy of creating a more centralized, scalable and efficient distribution network. The Company believes the award has the potential to increase fresh-cut herb volume and improve operating efficiencies as demand grows, while providing a foundation for Edible Garden to pursue additional stores, products and regional opportunities with Walmart and other major retailers.

“This award represents another important expansion of our relationship with Walmart and establishes an additional supply-chain position for Edible Garden in the Upper Midwest,” said Jim Kras, Chief Executive Officer of Edible Garden. “We believe it reflects Walmart’s confidence in our ability to consistently deliver fresh, high-quality herbs while meeting the food-safety, reliability, and service requirements of one of the world’s largest retailers. Just as importantly, the award advances our transition toward a more efficient distribution-center model. By consolidating shipments through Walmart’s distribution network, we believe we can improve route density, reduce fragmented deliveries and scale more efficiently as demand grows, while reducing unnecessary transportation, handling, and potential food waste. This approach supports our Zero-Waste Inspired® mission while building a stronger and more resilient distribution platform that can support our fresh herb business today and provide a commercial foundation for future Farm-to-Formula® products and other opportunities across our broader food and nutrition portfolio.”

Edible Garden’s distribution strategy is supported by its proprietary GreenThumb 2.0™ technology, which helps the Company synchronize growing, inventory, and retailer demand. By improving visibility across its supply chain, the Company seeks to enhance forecasting and fulfillment, preserve product freshness and reduce excess inventory and waste.

Edible Garden’s work with Walmart also reflects the Company’s broader commitment to sustainable operations. The Company is a multi-year participant in Walmart’s Project Gigaton and has been recognized as a Giga Guru for its efforts to measure, manage and reduce emissions across its operations and supply chain.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

WARSAW, Ind., Sept. 22, 2026 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the recent implantation of the 1,000^th Tibia Nail using its latest Pediatric Nailing Platform (PNP).

The PNP Tibia System was designed to bring a world-class, pediatric-focused nailing system to surgeons, enabling the use of rigid tibial nails in pediatric patients.

OrthoPediatrics’ introduction of the 7mm cannulated rigid tibial nail, the only product of its size, enables surgeons to treat patients who have previously been untreatable with adult systems. In fact, nearly 20% of all nails implanted by OrthoPediatrics have been the smallest 7mm size available. The implant is available in 7mm-12mm diameters.

Joe Hauser, President of Trauma & Deformity, stated, “The rapid adoption of this system demonstrates that OrthoPediatrics is filling a critical void in implant offerings to our core customer. The surgeon design team and our OrthoPediatrics engineers were meticulous in developing a system purpose-built for the needs of pediatric patients, and it is proving to be a valuable tool in treating over 1,000 kids with tibia fractures.”

The system includes small instruments to access the intramedullary canal, smaller overall nails, fixation options designed to avoid the physis, and instrumentation supporting both traditional and suprapatellar approaches.

PNP Tibia is currently available in five markets, with a European launch planned for 2027.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 90 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.

Investor Contact
Philip Taylor
Gilmartin Group
philip@gilmartinir.com

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –

– Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses –

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that new data from the Phase 3 INDIGO trial evaluating obexelimab in immunoglobulin G4-related disease (IgG4-RD) will be presented at two upcoming scientific meetings: the 6^th International Symposium on IgG4-Related Disease, taking place October 8-10, in Cambridge, Massachusetts, and American College of Rheumatology (ACR) Convergence 2026, taking place November 6-11, 2026, in Orlando, Florida.

Longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6^th International Symposium on IgG4-Related Disease. Additional presentations across both meetings include analyses evaluating glucocorticoid-associated toxicity and vaccine responses among patients with IgG4-RD treated with obexelimab.

“Zenas is committed to advancing the scientific understanding of IgG4-RD and the potential role of obexelimab in addressing the needs of people living with this rare, chronic, immune-mediated disease,” said Lisa von Moltke, MD, Head of Research and Development and Chief Medical Officer of Zenas. “The upcoming presentations at the IgG4ward! 6^th International Symposium on IgG4-RD and ACR Convergence 2026 build on the Phase 3 INDIGO results presented earlier this year and reflect our continued focus on advancing therapies that may help people living with IgG4-RD.”

Presentation Details

Details of 6^th International Symposium on IgG4-Related Disease Presentations:

Title: Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
Presenting Author: Guy Katz, MD, MS – Massachusetts General Hospital
Session: Poster Viewing Session
Session Date & Time: Thursday, October 8; 5:00-7:00pm ET
Location: Charles Hotel-Boston

Title: Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients with IgG4-Related Disease: Results From the Phase 3 Randomized, Placebo-Controlled INDIGO Trial
Presenting Author: Matthew Baker, MD, MS – Stanford University
Session: Oral Presentation
Session Date & Time: Saturday, October 10; 9:00am ET
Location: Charles Hotel-Boston

Title: Longer-Term Efficacy and Safety of Obexelimab in IgG4-Related Disease: Results from the Phase 3 INDIGO Open-Label Extension
Presenting Author: Emma Culver, Dphil, MBChB – University of Oxford
Session: Oral Presentation
Session Date & Time: Saturday, October 10; 9:40am ET
Location: Charles Hotel-Boston

Details of ACR Convergence 2026 Presentations:

Title: Obexelimab Reduced Glucocorticoid-Associated Toxicity in Patients with IgG4-Related Disease: Results from the Phase 3 Randomized, Placebo-Controlled INDIGO Trial
Presenting Author: Matthew Baker, MD, MS – Stanford University
Session: Miscellaneous Rheumatic & Inflammatory Diseases I
Session Date & Time: Monday, November 9; 1:30pm-1:45pm ET
Abstract Number: 1882
Location: Oral presentation, W304 A-H

Title: Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in Patients with IgG4-RD
Presenting Author: Guy Katz, MD, MS – Massachusetts General Hospital
Session: Miscellaneous Rheumatic & Inflammatory Diseases; Poster Session C
Session Date & Time: November 10; 10:30am-12:30pm ET
Abstract Number: 2612
Location: Poster Hall

About Obexelimab
Obexelimab is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. This unique inhibitory mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively modulate the pathogenic role of the B cell lineage in chronic autoimmune disease.

Obexelimab has been evaluated in nine clinical trials in a total of 667 subjects, including INDIGO. Obexelimab was well tolerated and demonstrated clinical activity across these clinical trials.

Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) topline results expected in 4Q 2026.

About IgG4-RD
IgG4-related disease (IgG4-RD) is a rare, chronic immune-mediated disease that can cause inflammation and fibrosis in multiple organs throughout the body. Because symptoms can appear suddenly or develop gradually—and may be mistaken for other conditions—many people face a 5–7-year journey to diagnosis. IgG4-RD can worsen and cause irreversible damage if it is not diagnosed and managed properly. About 20,000 people in the United States have been diagnosed with IgG4-RD, but the true number of people living with the disease may be closer to 40,000 because some individuals remain undiagnosed.

About Zenas BioPharma
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements.” In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward looking statements include, but are not limited to, the anticipated timing or likelihood of regulatory submissions and approvals, and the outcome of interactions with regulatory authorities; the therapeutic potential of the Company’s product candidates; the Company’s expectations regarding the potential commercialization, estimated market size and market opportunities of its product candidates; and the timing of reporting the topline results of obexelimab in SLE. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results, performance or achievements to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements; the Company’s ability to obtain regulatory approval to commercialize its product candidates; risks related to the manufacturing of the Company’s product candidates and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the its license obligations; significant political, trade, and regulatory developments, including changes in relations between the U.S. and China; risks related to the operations of the Company’s suppliers, many of which are located outside of the United States, including the Company’s current sole contract manufacturing organization for obexelimab drug substance and drug product, WuXi Biologics (Hong Kong) Limited, and our partner, InnoCare, both of which are located in China; the risk that the Company’s indebtedness could adversely affect the Company’s financial condition or restrict the Company’s future operations; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented from time to time by our subsequent filings with the Securities and Exchange Commission (the “SEC”), as well as other information we file with the SEC. The forward-looking statements in this press release are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete. Because forward-looking statements are inherently subject to risks and uncertainties, these forward-looking statements should not be relied upon as guarantees of future events. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Contacts:

Investors:
Argot Partners
Zenas@argotpartners.com

Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Ruihe Data Technology Holdings Limited (HKEX: 3680; OTCQX: RHDTY), an investment holding company, has qualified to trade on the OTCQX® Best Market. Ruihe Data Technology Holdings Limited upgraded to OTCQX from the Pink Limited™ Market.

Ruihe Data Technology Holdings Limited begins trading today on OTCQX under the symbol “RHDTY.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Ruihe Data Technology Holdings Limited is a leading enterprise in China’s data intelligence and marketing technology. It provides financial institutions, government agencies, and enterprises with solutions and consulting services in big data decision-making, artificial intelligence, digital marketing, and the domestic information technology innovation industry.

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

“The Company regards the upgrade from the Pink Limited Market to the OTCQX Market as a significant milestone. It showcases the Company’s qualifications and raises its profile among U.S. investors. This upgrade is expected to broaden the Company’s investor base and enhance liquidity, aligning with the interests of the Company and its shareholders,” said Ruihe Data Technology Holdings Ltd. Chairman and CEO Shouguang Xue.

Trading in Asia Pacific securities on the OTC Markets reached U.S. $19.49B in the second quarter of 2026, representing a 34.1% increase over Q2 2025. OTC Markets recorded U.S. $453.34B in total dollar volume in the first half of the year. Asia Pacific markets ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Ruihe Data Technology Holdings Limited
The Company is a company incorporated in the Cayman Islands with limited liability and is an investment holding company. The Group is principally engaged in the provision of data solutions, integrated sales of hardware and software and related services, information technology maintenance and support services, commodity trading, cryptocurrency mining and investment in high-tech business

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com